参考文献

［1］National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology（NCCN Guidelines）：Ovarian cancer.Version 1.2013［Z／OL］.2012－11－16.http：／／www.nccn.org／professionals／physician＿gls／pdf／ovarian.pdf.

［2］Berek J S，ChjhRalas E，Edelson M，et al.Prophylactic and risk－Reducing bilateral salpingo－oophorectomy：recommendations based on risk of ovarian cancer［J］.Obstet Gynecol，2010，116（3）：733－743.

［3］Coleman R L，Ramirez P T，Gershenson D M.Neoplastic diseases of the ovary：screen－ing，benign and malignant epithelial and germ cell neoplasms，sex－cord stromal tumors［M］／／Lentz G M，Lobo R A，Gershenson D M，et al.Comprehensive Gynecology.6th ed.Philadelphia，PA：Elsevier Mosby，2012.

［4］Berek J S，Crum C，Friedlander M.FIGO cancer report 2012，Guest Editor：Lynette Danny［J］.Int J Gynecol Obstet，2012，119：s11830－s12936.

［5］Colombo N，Kutarska E，Dimopolos M，et al.Randomized，open－label，phaseⅢstudy comparing patupilone（EPO906）with pegylated liposomal doxorubicin in platinum－refractoryor－resistant patients with recurrent epithelial ovarian，primary fallopian tube，or primary peritoneal cancer［J］.J Clin Oncol，2012，30（31）：3841－3847.

［6］Armstrong D K，Bundy B，Wenzel L，et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer［J］.N EngI J Med，2006，354：34－43.(https://www.daowen.com)

［7］Mcguire W P，Hoskins W J，Brady M F，et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stageⅢand stageⅣovarian cancer［J］.N Engl J Med，1996，334：1－6.

［8］Mutch D G，Prat J.2014FIGO staging for ovarian，fallopian tube and peritoneal cancer［J］.GynecolOncol，2014，133（3）：401－404.

［9］Committee on Gynecologic Practice.Committee opinion no.620：salpingectomy for ovarian cancer prevention［J］.Obstet Gynecol，2015，125（1）：279－281.

［10］Frey M K，Kim S H，Bassett R Y，et al.Rescreening for genetic mutations using multi－gene panel testing in patients who previously underwent non－informative genetic screening［J］.Gynecol Oncol，2015，139（2）：211－215.

［11］Tewari D，Java J J，Salani R，et al.Long－term survival advantage and prognostic factors associated with ovarian cancer：agynecologic oncology group study［J］.J Clin Oncol，2015，33（13）：1460－1466.